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Claudio Cobelli, Bernard R. Landau, Robert A. Rizza, and Ole Schmitz
Impaired glucose effectiveness (i.e., a diminished abil-
ity of glucose per se to facilitate its own metabolism),
increased gluconeogenesis, and endogenous glucose
release are, together with insulin resistance and -cell
abnormalities, established features of type 2 diabetes.
To explore aspects of the pathophysiology behind
type 2 diabetes, we assessed in a group of healthy peo-
ple prone to develop type 2 diabetes (n = 23), namely
first-degree relatives of type 2 diabetic patients (FDR),
1) endogenous glucose release and fasting gluconeoge-
nesis measured using the 2H2O technique and 2) glucose
effectiveness. The FDR group was insulin resistant
when compared with an age-, sex-, and BMI-matched
control group without a family history of type 2 diabetes
(n = 14) (M value, clamp: 6.07 ± 0.48 vs. 8.06 ±
0.69 mg · kg–1 lean body weight (lbw) · min–1; P = 0.02).
Fasting rates of gluconeogenesis (1.28 ± 0.06 vs. 1.41 ±
0.07 mg · kg–1 lbw · min–1; FDR vs. control subjects, P =
0.18) did not differ in the two groups and accounted for
53 ± 2 and 60 ± 3% of total endogenous glucose
release. Glucose effectiveness was examined using a
combined somatostatin and insulin infusion (0.17 vs.
0.14 mU · kg–1 · min–1, FDR vs. control subjects), the lat-
ter replacing serum insulin at near baseline levels. In
addition, a 360-min labeled glucose infusion was given
to simulate a prandial glucose profile. After glucose
infusion, the integrated plasma glucose response above
baseline (1817 ± 94 vs. 1789 ± 141 mmol/l per 6 h), the
ability of glucose to simulate its own uptake (1.50 ± 0.13
vs. 1.32 ± 0.16 ml · kg–1 lbw · min–1), and the ability of
glucose per se to suppress endogenous glucose release
did not differ between the FDR and control group. In
conclusion, in contrast to overt type 2 diabetic
patients, healthy people at high risk of developing
type 2 diabetes are characterized by normal glucose
effectiveness at near-basal insulinemia and normal
fasting rates of gluconeogenesis. Diabetes 49:2135–
2141, 2000
Type 2 diabetes is characterized by a large numberof hormonal and metabolic abnormalities includ-ing insulin resistance, impaired glucose effective-ness, augmented gluconeogenesis, and disturbed
islet cell secretion (1,2). An inherited component is strongly
involved in the pathogenesis of the disease, but lifestyle and
other environmental factors also contribute. Hence, it is esti-
mated that the lifetime risk of developing type 2 diabetes is
between 40 and 60% in first-degree relatives of type 2 diabetic
patients (FDR) (3,4). Because the metabolic derangement in
type 2 diabetes per se is able to induce hormonal and meta-
bolic abnormalities, it is not possible to evaluate to what
extent the aberrations in type 2 diabetic patients are of pri-
mary pathophysiological significance or if they merely reflect
glucose toxicity. To circumvent this hindrance, healthy peo-
ple at a substantial risk of developing type 2 diabetes, e.g.,
FDR, are often examined to cast light on mechanisms behind
development of the disease.
Many studies report impaired insulin-stimulated glucose
uptake in these healthy but potentially prediabetic individu-
als (4–11). In addition, an increasing number of studies have
demonstrated, by using different experimental designs,
defects in -cell function (9–12). However, the function of
other important regulators of glucose homeostasis are not
well defined in FDR. Thus, gluconeogenesis, which con-
tributes considerably to hyperglycemia in diabetes, has not
been assessed nor has the ability of glucose to facilitate its
own metabolism (i.e., to stimulate glucose uptake and sup-
press glucose release). That ability has attracted increasing
interest, especially in insulin-resistant states, in which glucose
effectiveness may play a pivotal compensatory role in pro-
moting glucose uptake. In particular, it has been suggested,
by using the frequently sampled intravenous glucose tolerance
test (FSIGT) and the minimal model, that an increased glucose
effectiveness may act as a compensatory mechanism main-
taining normal glucose tolerance in insulin-resistant FDR
(13). However, whereas FSIGT minimal model analysis pro-
vides estimates of insulin sensitivity comparable to those
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from the glucose clamp technique (14,15), recent studies
have questioned the model’s ability to accurately assess glu-
cose effectiveness (16–19). To overcome these potential
errors, an alternative approach was recently introduced
(20,21). Briefly, during somatostatin infusion and baseline
replacement of insulin (and glucagon and growth hormone),
a prandial plasma glucose profile is simulated by a dynamic
glucose infusion. Using the labeled exogenous glucose
infusates, this model allows simultaneous assessment of glu-
cose-mediated glucose uptake and endogenous glucose
release and thus estimation of glucose effectiveness on both
peripheral use and glucose production.
The present study was consequently undertaken to
gain further insight into cardinal aspects of glucose
metabolism in healthy relatives of type 2 diabetic indi-
viduals. The first step was to reappraise the ability of
glucose to facilitate its own uptake and suppress its own
production by using the above approach during constant
(near)-baseline insulin concentrations and a dynamic
glucose infusion simulating prandial glucose excursion.
The second step was to determine whether gluconeoge-
nesis is already abnormal in the prediabetic state. The lat-
ter was assessed by combining the isotope dilution
method with the deuterated water technique to measure
the fractional contribution of gluconeogenesis to glucose
production (22,23).
RESEARCH DESIGN AND METHODS
Subjects. After approval from the Ethical Committee, County of Aarhus, 23
healthy FDR and 14 healthy subjects without any family history of diabetes gave
written consent to participate in the study. All participants were Caucasian.
Within the group of FDR, 5 had two first-degree relatives, 13 had one parent and
two or more second-degree relatives, and 5 had only one parent with type 2 dia-
betes. The FDR and control subjects were from unrelated families, and the two
groups were matched for age, sex, and BMI. All exhibited a normal oral glucose
tolerance test (75 g glucose) according to World Health Organization criteria.
The clinical data of the two groups are recorded in Table 1. None of the
recruited subjects were taking any medication. At least 3 days before study, sub-
jects were instructed not to engage in vigorous exercise.
Experimental design. All subjects underwent a hyperinsulinemic-eugly-
cemic clamp and a prandial glucose infusion test; this test was preceded by
a labeled water experiment. Examinations were separated by at least 2 weeks
and were performed in random order.
Euglycemic-hyperinsulinemic clamp. After an overnight fast (from 2200),
subjects were admitted to the clinical research center at 0730. At 0800, an
18-gauge cannula was inserted into a dorsal hand vein. The hand was then kept
in a heated Plexiglas box (55°C) to allow sampling of arterialized venous
blood. In addition, a cannula was placed in an antecubital vein to be used for
infusions. After 90 min, an infusion of insulin at a rate of 0.6 mU · kg–1 · min–1
was started and maintained for 150 min. An infusion of 20% glucose was also
started, and the infusion rate was adjusted to keep the plasma glucose con-
centration at ~5 mmol/l. The amount of glucose (milligrams per kilogram
lean body weight [lbw] per minute) required to maintain euglycemia during
the last 30 min of the clamp (i.e., time 120–150 min) was taken as an index of
insulin action (M value).
Labeled water and prandial glucose infusion test. Subjects were admit-
ted to the clinical research center at 2200 on the evening before the study. A
standard meal (carbohydrate content ~50%) was consumed between 1800
and 2000. At 0500, 0600, and 0700 on the following morning, the subjects
drank 1.7 ml of 2H2O (99.9% H; Cambridge Isotope Laboratories, Andover, MA)
per kilogram body water. Body water was calculated to be 50% of total body
weight in women and 60% of total body weight in men. Water ingested ad libi-
tum thereafter was enriched to 0.5% with 2H2O to maintain isotopic steady
state. At 0730 (time, –150 min), a primed continuous infusion of [3-3H]glucose
(17 µCi prime, 0.17 µCi/min continuous) was started and continued to the
end of the study to measure endogenous glucose release (EGR) and glucose
disposal rate. During the prandial glucose infusion, the rate of continuous
[3-3H]glucose was changed to clamp specific activity (see below). Blood was
collected at –60, –30, and 0 min to determine the fractional contribution of glu-
coneogenesis to EGR (Fig. 1).
A 6-h preprogrammed variable glucose infusion was started at time zero
using an infusion pump (model PhD 2000, Harvard Apparatus, South Natick,
MA), driven by a PC2/30 265 Computer (IBM, Rochester, MN). Glucose was
infused in a manner (21) mimicking the systemic rate of appearance of glucose
that occurs after ingestion of 50 g of glucose. The pattern and amount of glu-
cose and tracer infused normalized to lean body mass was equal in the two
groups. Furthermore, at time zero, an infusion containing somatostatin (Fer-
ring, Kiel, Germany) (60 ng · kg–1 · min–1), glucagon (Novo Nordisk, Bagsværd,
Denmark) (time 0–120 min, 0.65 ng · kg–1 · min–1; time 120–360 min,
1.30 ng · kg–1 · min–1), and growth hormone (Novo Nordisk) (2 ng · kg–1 ·
min–1) was also started. Finally, a constant basal insulin infusion (Insulin
Actrapid; Novo Nordisk) was started at rates of 0.17 mU · kg–1 · min–1 in the
FDR (n = 23) and at 0.14 mU · kg–1 · min–1 in the control subjects (n = 10). These
basal insulin infusion rates were chosen based on previous experiments in
which basal insulin concentrations were determined individually (20,24,25) and
the fact that fasting insulin concentrations were expected to be higher in the
FDR group because of insulin resistance. However, to assess glucose effec-
tiveness during matched basal insulin concentrations in the control and FDR
groups, an additional experiment was performed in the control subjects in
which basal insulin was infused at 0.17 mU · kg–1 · min–1 (n = 13). The two
experiments were done in random order.
In an effort to maintain constant specific activities during the experiments,
the rate of basal [3-3H]glucose was adjusted (time –150 to 0 min, 100%; 0–30 min,
70%; 30–60 min, 46%; 60–90 min, 55%; 90–120 min, 53%; 120–150 min, 58%;
150–210 min, 61%; and 210–360 min, 65%) according to the anticipated sup-
pression of EGR during the glucose infusion. In addition, all glucose infusions
contained [3-3H]glucose (26). Hence, plasma glucose specific activity
remained constant during the glucose infusion in both groups.
Analytical techniques. Arterialized plasma glucose samples were measured
in duplicate immediately after sampling (Beckman Instruments, Palo Alto,
CA). Samples for hormone analysis were placed on ice, centrifuged at 4°C, sep-
arated, and stored at –20°C until assay. Serum insulin was determined by two-
site enzyme-linked immunosorbent assay (27). Plasma glucagon, serum growth
hormone, and C-peptide concentrations were measured by radioimmunoassay.
Serum free fatty acids (FFAs) were measured enzymatically using a Wako
NEFA (nonesterified fatty acid) Test Kit (Wako Chemicals, Neuss, Germany).
The measurement of deuterium enrichment on carbon 2 and 5 in glucose
was performed as previously described (23). Briefly, 15 ml blood was diluted
with 30 ml demineralized water and deproteinized using 15 ml of 0.3N ZnSO4
and 15 ml of 0.3N Ba(OH)2. The samples were centrifuged at 2,000 rpm for 15 min,
and the pellet was diluted in 15 ml demineralized water to wash out the
remaining glucose. Glucose was isolated by successive ion-exchange chro-
matography and high-performance liquid chromatography. For determina-
tion of deuterium enrichment on C5, glucose was first converted to xylose, and
the carbon 5 of glucose with its hydrogens was cleaved by periodate oxida-
tion to formaldehyde, which was condensed with ammonium hydroxide to
form hexamethylenetetramine (HMT). The 2H bound to C2 of glucose was iso-
lated after conversion of glucose to ribitol-5-phosphate and arabitol-5-phos-
phate and treated to form HMT. HMT was analyzed on a Hewlett-Packard mass
spectrometry system. Standard solutions of glucose of known enrichment were
run along with the unknown samples to calibrate for instrument variations.
Calculation of glucose turnover. Glucose appearance and disappearance
were calculated using Steele’ s equations for non–steady state (28) after
smoothing of glucose specific activity using the method of Bradley et al. (29).
EGR was determined by subtracting the glucose infusion rate from the tracer-
determined rate of glucose appearance. The fractional contribution of gluco-
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TABLE 1
Subject characteristics
Control 
FDR subjects
Age (years) 34 ± 2 34 ± 2
Sex (M/F) 12/11 7/7
BMI (kg/m2) 25.8 ± 0.5 25.0 ± 0.7
Waist-to-hip ratio 0.87 ± 0.01 0.86 ± 0.01
Lean body weight (% of body weight) 74 ± 2 73 ± 3
Fasting plasma glucose (mmol/l) 5.4 ± 0.1* 5.1 ± 0.0
Fasting serum insulin (pmol/l) 40 ± 4* 25 ± 2 
M value (mg · kg–1 lbw · min–1) 6.07 ± 0.48 8.06 ± 0.69
Data are means ± SE. *P < 0.05.
neogenesis to glucose production equals the ratio between deuterium bound
to carbon 5 in glucose to that bound to carbon 2 (23). A quantitative estimate
of baseline gluconeogenesis was determined by multiplying the mean EGR
from time –30 to 0 min by the mean of the fractional contribution from time
–60 to 0 min.
Assessment of glucose effectiveness from area under the curve
calculations. The calculations of the three indexes of glucose effectiveness—
net glucose effectiveness (GEb), index of the ability of glucose to stimulate its
own uptake (GEb*), and index of the ability of glucose to suppress its own pro-
duction (GEliver)—from plasma glucose and tracer concentrations have been
described in detail elsewhere (20). Net glucose effectiveness at basal insu-
linemia, i.e., the combined effect of glucose to suppress its own production and
stimulate its own uptake (GEb) was calculated as the ratio between the area
under the curve (AUC) of the exogenous glucose infusion rate (GIR) and the
AUC of the glucose concentration above basal (G):
GEb =
AUC [GIR(t)]
 (ml · kg–1 lbw · min–1)
AUC [G(t)]
Because equal amounts of glucose were infused in the groups, the excur-
sion of glucose concentration above basal was inversely related to net glucose
effectiveness in the two groups. The greater the glycemic excursion, the
lower the net glucose effectiveness (GEb). Disposal glucose effectiveness, i.e.,
the ability of glucose to stimulate its own uptake (GEb*), was also calculated
as described by Basu et al. (20):
GEb* =
{AUC [GIR*(t)]  PCRb Gb AUC [SA(t)]}  (ml · kg–1 lbw · min–1)
{AUC [G*(t)]  Gb AUC [SA(t)]}
where GIR* is the tracer infusion rate above the basal rate, G* is tracer
glucose concentration, SA is the tracer specific activity, Gb is the baseline
glucose concentration, and PCRb is the basal plasma glucose clearance rate.
 Denotes the excursion of each variable above basal. Finally, the effect of glu-
cose on EGR (GEliver, ml · kg
–1 lbw · min–1) was calculated by subtracting GEb*
from net glucose effectiveness (GEb).
Statistical analysis. Data in the text and figures are expressed as means ±
SE. All rates and indexes are expressed per kilogram lean body weight.
Responses above or below baseline were calculated using the trapezoidal
rule. Basal is defined as the mean of the values present during the 30 min before
the prandial glucose infusion. Nonpaired Student’s t test was used for statis-
tical comparison between FDR and control subjects (either 0.14 or 0.17
mU · kg–1 · min–1). A P value <5% was considered statistically significant.
RESULTS
Fasting glucose and hormone concentrations and insulin
sensitivity. After overnight fasting, plasma glucose (5.4 ± 0.1
vs. 5.1 ± 0.1 mmol/l; P = 0.02), serum insulin (40 ± 5 vs. 25 ±
2 pmol/l; P = 0.02), and C-peptide (509 ± 29 vs. 434 ± 18 pmol/l;
P = 0.07) concentrations were higher in FDR than in control sub-
jects. Fasting plasma glucagon (49 ± 4 vs. 53 ± 6 ng/l; P = 0.55)
and serum growth hormone (0.3 ± 0.1 vs. 1.2 ± 0.9 µg/l; P = 0.22)
concentrations were similar in the two groups.
The amount of glucose required to maintain euglycemia dur-
ing the hyperinsulinemic clamp was lower in the FDR than in
control subjects (6.07 ± 0.48 vs. 8.06 ± 0.69 mg · kg–1 lbw · min–1;
P = 0.02), indicating the presence of insulin resistance in the
former group. There was no relationship between insulin sen-
sitivity and family history of diabetes.
Fasting endogenous glucose release and gluconeogenesis.
Rates of EGR (2.40 ± 0.06 vs. 2.37 ± 0.10 mg · kg–1 lbw · min–1;
P = 0.79) and gluconeogenesis (1.28 ± 0.06 vs. 1.41 ±
0.07 mg · kg–1 lbw · min–1; P = 0.18) did not differ between
groups despite elevated circulating insulin concentrations
in the FDR. Gluconeogenesis accounted for 53 ± 2 and 60 ±
3% of total EGR in the FDR and control subjects, respec-
tively (Fig. 2).
Substrate and hormone concentrations during pran-
dial glucose infusion. During basal insulin infusion (0.17 vs.
0.14 mU · kg–1 · min–1, FDR vs. control subjects), average
serum insulin concentrations (time 0–360 min) were higher
in FDR than in control subjects (66 ± 4 vs. 54 ± 4 pmol/l; P =
0.03). As expected, circulating insulin concentrations did not
differ in the two groups when applying identical infusion
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FIG. 1. Experimental design as described in the text.
FIG. 2. Fasting rates of EGR () and gluconeogenesis () in FDR and
control subjects. Gluconeogenesis was calculated by multiplying the
mean ratio of deuterium enrichment at carbon 5 to that at carbon 2
in glucose by the mean rate of fasting EGR from –60 to 0 min.
rates (0.17 mU · kg–1 · min–1) (66 ± 4 vs. 61 ± 3 pmol/l; P = 0.58).
During somatostatin infusion, C-peptide concentrations were
equally suppressed (76 ± 12 vs. 79 ± 10 vs. 60 ± 8 pmol/l per
6 h, FDR vs. control subjects [0.14 mU · kg–1 · min–1]) versus con-
trol subjects (0.17 mU · kg–1 · min–1), indicating comparable inhi-
bition of endogenous insulin secretion during glucose infu-
sion. Plasma glucagon (104 ± 10 vs. 102 ± 7 vs. 114 ± 4 ng/l) and
growth hormone (0.41 ± 0.4 vs. 0.55 ± 0.10 vs. 0.43 ± 0.03 µg/l)
concentrations did not differ during the three examinations. All
hormone concentrations remained constant and equal during
glucose infusion. Serum FFA concentrations declined
promptly after insulin and glucose infusion and remained
equally suppressed in the FDR and control subjects (62 ± 9 vs.
45 ± 7 vs. 46 ± 8 mmol/l per 6 h) (Figs. 3 and 4).
Estimates of glucose effectiveness. After initiation of the
prandial glucose infusion, the glycemic excursion did not
differ in control subjects (0.14 mU · kg–1 · min–1) and FDR,
whether measured as peak plasma glucose concentration
(13.3 ± 0.4 vs. 13.4 ± 0.2 mmol/l; P = 0.71) or integrated
response above baseline (1,789 ± 141 vs. 1,817 ± 94 mmol/l per
6 h; P = 0.87), indicating that net glucose effectiveness (see
below) was similar in the two groups. During the higher
insulin infusion rate in control subjects (0.17 mU · kg–1 ·
min–1), peak plasma glucose (12.2 ± 0.5 vs. 13.4 ± 0.2 mmol/l;
P = 0.01) as well as the glycemic excursion above baseline
(1,408 ± 153 vs. 1,817 ± 94 mg/kg per 6 h; P = 0.02) was lower
in the control subjects than in the FDR (Figs. 3, 5, and 6).
GEb was almost identical in control subjects (0.14 mU · kg
–1 ·
min–1) and FDR (2.59 ± 0.17 vs. 2.61 ± 0.25 ml · kg–1 lbw · min–1;
P = 0.94) during basal insulinemia. However, when control
subjects were infused with insulin at an rate equivalent to that
of FDR (0.17 mU · kg–1 · min–1), GEb was higher in the control
subjects (3.84 ± 0.56 ml · kg–1 lbw · min–1) compared with the
FDR (P < 0.01). Neither GEb* (the ability of glucose to stimu-
late its own uptake) (1.32 ± 0.16 vs. 1.50 ± 0.13 ml · kg–1 lbw ·
min–1, control subjects vs. FDR, P = 0.42) nor the effect of glu-
cose to suppress glucose production (GEliver) (1.3 ± 0.3 vs.
1.1 ± 0.2 ml · kg–1 lbw · min–1, control subjects vs. FDR, P = 0.49)
differed between the two groups during near-basal insulinemia.
Furthermore, the dynamic alterations of EGR during hyper-
glycemia were comparably suppressed in the groups (P =
0.88). Of note, plasma [3-3H]glucose specific activity was main-
tained within ~10% of basal values in all experiments (Fig.5).
DISCUSSION
The present study explores two important aspects of glu-
cose metabolism in FDR, i.e., people at risk of developing
type 2 diabetes. First, it demonstrates that fasting gluconeo-
genesis and the ability of glucose per se to restrain EGR are
unaltered in FDR and a matched control group. Second, it
demonstrates that glucose effectiveness, as assessed by the
labeled glucose infusate technique during a dynamic glucose
infusion mimicking the systemic rate of appearance of glucose
that occurs after ingestion of 50 g glucose, is similar in FDR
and control subjects at near-basal insulinemia.
In type 2 diabetes, glucose production is inappropriately
high for the prevailing glucose and insulin concentrations
(30–32). Using different techniques, both animal and human
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FIG. 3. Plasma glucose, serum insulin, and C-peptide concentrations
in the FDR and control subjects during the prandial glucose infusion.
The glucose infusion was started at 0 min.
FIG. 4. Plasma glucagon, serum growth hormone, and FFA concentra-
tions in the FDR and control subjects during the prandial glucose
infusion. The glucose infusion was started at 0 min.
studies indicate that diabetes is associated with markedly
increased rates of gluconeogenesis (33–36). However, to our
knowledge, rates of gluconeogenesis have never been deter-
mined in healthy FDR. In the present study, the deuterated
water technique (22,23) was applied to assess gluconeogen-
esis in the fasting state. Deuterated water was ingested after
an ~12-h fast to minimize incorporation into glycogen. The
fractional contribution of gluconeogenesis to EGR was deter-
mined as the ratio of 2H in position 5 in glucose to that of 2H
in position 2 of glucose. Postabsorptive rates of gluconeoge-
nesis were calculated by multiplying this rate by EGR.
Not only fasting EGR but also rates of fasting gluconeo-
genesis were similar in the two groups. Of notice is that com-
parable gluconeogenesis and consequently rates of
glycogenolysis between groups are present under the con-
dition of elevated insulinemia in FDR, suggesting hepatic
insulin resistance. The kidneys contribute little EGR after
12 h of fasting (37). The presence of normal rates and frac-
tions of gluconeogenesis in FDR suggests, but does not
prove, that the increased gluconeogenesis in type 2 dia-
betes is secondary to the metabolic derangement and is not
an inherited phenomenon. To some extent, the increase
could be ascribed to the glucagon excess in type 2 diabetes.
However, our FDR exhibited normal fasting plasma
glucagon levels, in accordance with recent data demon-
strating normal diurnal concentrations of glucagon in off-
spring of type 2 diabetic patients (11). On the other hand, one
could reason that possible and discrete inherited abnor-
malities in hepatic glucose handling in FDR are balanced by
compensatory insulin hypersecretion in contrast to overt
type 2 diabetic individuals with more limited -cell capacity.
In addition to hormones, nonhormonal factors regulate
EGR. Glucose per se is a potent suppressor of hepatic glucose
release (38,39). Both in vivo and in vitro studies indicate that
glucose can decrease EGR as much as 60–90% (40). After an
overnight fast, this action of glucose is mainly believed to be
mediated via inhibition of net hepatic glycogenolysis through
reduction of glycogen phosphorylase flux (41). The current
study clearly demonstrates that the restraining effect of a
prandial glucose profile on EGR is normal in FDR. After glu-
cose infusion, EGR was again equally suppressed in the
groups, suggesting that hepatic insulin resistance, rather than
a reduced ability of hyperglycemia to suppress EGR, consti-
tutes the main defect in the regulation of hepatic glucose
metabolism in FDR.
Permissive amounts of insulin are required for glucose to
suppress EGR (42,43). As in previous experiments (20,24,42),
we aimed in our primary design to maintain a near-baseline
insulin concentration during somatostatin infusion by
replacement of insulin at different doses in FDR and control
subjects (0.17 vs. 0.14 mU · kg–1 · min–1, respectively). In both
groups, circulating peripheral insulin concentrations were
~25 pmol/l higher during the pancreatic clamp than during fast-
ing. With an almost zero endogenous insulin secretion, this is
presumably equivalent to normal fasting insulin concentrations
in the portal vein. It should be emphasized that the differ-
ence in the observed fasting serum insulin concentrations
between the two groups was preserved during pancreatic
clamping (15 vs. 12 pmol/l). Finally, these data are in accor-
dance with recent studies in which dose dependency of glu-
cose to decrease EGR (and gluconeogenesis) within the phys-
iological area of glucose was found to be comparable in type 2
diabetic and nondiabetic individuals (42,44). Because of pos-
sible incorporation of 2H from 2H2O into glycogen during glu-
cose infusion, the present design did not allow us to reliably
assess gluconeogenesis during prandial hyperglycemia.
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FIG. 5. Endogenous glucose release and [3-3H]glucose specific activ-
ity in the FDR and control subjects before and during the prandial glu-
cose infusion. The glucose infusion was started at 0 min.
FIG. 6. Estimates of glucose effectiveness determined during near-
basal insulin concentrations in FDR and control subjects. Insulin infu-
sion rates were 0.17 vs. 0.14 mU · kg–1 · min–1, respectively. GEb con-
stitutes the combined effects of glucose to stimulate its own uptake
(GEb*) and suppress its own production (Geliver).
The second important issue examined in the current study
was the ability of glucose to promote its own uptake. After
meal ingestion, the rate at which glucose is normalized is
determined by the combined effects of insulin action and
glucose effectiveness. Whereas FDR are characterized by
insulin resistance, it is unclear whether glucose effective-
ness also is altered in these individuals. This is a cardinal ques-
tion because approximately half of the decline in plasma glu-
cose concentration after glucose administration in healthy
individuals has been suggested to be due to the mass action
effect of hyperglycemia (45).
The classic FSIGT, without concomitant tracer injection,
has proven useful in the measurement of insulin action, but
its ability to accurately measure glucose effectiveness is less
clear. It has been demonstrated (17–19) that the cold minimal
model results in an overestimation of net glucose effective-
ness when assessed in the presence of rapidly changing glu-
cose and insulin concentrations.
Consequently, in the present experiment, glucose effec-
tiveness was determined using an optimized minimal model
independent protocol in which constant near-basal circulating
insulin concentrations were maintained during glucose infu-
sions, simulating a meal (20,21). Near-basal insulin concen-
trations were achieved by infusing insulin (concomitant with
somatostatin) at rates of primarily 0.14 mU · kg–1 · min–1 in the
control group and 0.17 mU · kg–1 · min–1 in the FDR. The
rationale for using these infusion rates has been mentioned
above. Whereas the difference in serum insulin between con-
trol subjects and FDR was maintained and portal insulin lev-
els probably were replaced at basal levels, the insulin infusion
rates were accompanied by a doubling of peripheral serum
insulin concentrations. This difference may seem dramatic, but
the average circulating concentrations were still well below
81 pmol/l—the upper limit for fasting lean individuals. Fur-
thermore, without endogenous insulin secretion, an elevated
peripheral insulin level is mandatory to balance hepatic
metabolism. The insulin levels denoted near-basal are lower
than those achieved by other models, apart from studies using
non–insulin mediated glucose uptake with zero insulin (46).
During glucose infusion, plasma glucose concentrations
increased equally in the two groups, suggesting that glucose
effectiveness was similar in FDR and control subjects. This was
equally evident whether glucose effectiveness was measured
directly as the glycemic excursion above basal or whether
GEb and GEb* were calculated. As a consequence of the primary
design, basal serum insulin concentrations were higher in the
FDR than in the control subjects. This result is in contrast to
some studies that have examined glucose effectiveness in
FDR, and it could be reasoned that the difference in insulin
replacement between the groups might affect our estimate of
effectiveness. To address this question, insulin replacement in
the control group was also administered with an insulin infu-
sion rate identical to that of FDR (0.17 mU · kg–1 · min–1). This
replacement resulted in higher estimates of GE* in the control
subjects. On the basis of these data, a decreased glucose effec-
tiveness in FDR, as demonstrated in a previous report (4),
could be claimed. However, it is unlikely that this difference
reflects dissimilarity in glucose effectiveness per se but rather
is a result of an increased insulin action in control subjects com-
pared with FDR. Glucose effectiveness constitutes the ability
of glucose at basal circulating insulin concentrations to regu-
late its own metabolism. Basal serum insulin concentrations
refer to the concentrations required to obtain identical biologic
effects in the two groups, which by definition are higher in
insulin-resistant FDR than in control subjects, to compensate
for a reduced insulin sensitivity in the former.
Thus, the present study indicates that glucose effective-
ness is unaltered in FDR and suggests that insulin resistance
precedes the development of impaired glucose effectiveness
in frank type 2 diabetes. Our study confirms data by Osei et al.
(47) but is in conflict with Henriksen et al. (13), who by using
cold minimal model analysis (FSIGT) reported increased glu-
cose effectiveness in FDR and proposed that this could be a
protective response in people prone to develop type 2 diabetes.
Apart from differences in study design, the discrepancy
between the results of the latter study and ours are difficult
to resolve. However, the rapidly changing glucose and insulin
concentrations could possibly result in an overestimation of
the FSIGT variable glucose effectiveness  (SG) in insulin-resis-
tant FDR. Our data may at first glance also seem in contrast
with the study of Martin et al. (4), who found SG to be
decreased in FDR who later developed type 2 diabetes, again
using the minimal model. However, insulinemia was similar in
the prediabetic FDR compared with subjects who remained
normoglycemic, and their results can thus be extrapolated to
our data when applying identical insulin infusion rates in FDR
and control subjects.
Although knowledge of the mechanisms behind the ability
of glucose to promote its own uptake are still only rudimen-
tary, an increase in glucose concentration stimulates translo-
cation of GLUT4 transporters to the plasma membrane in
muscle (48), similar to the actions of insulin and contraction
on the GLUT4 transporters (49). This result could contribute
to the disturbed glucose effectiveness in overt type 2 diabetes,
although our data conceivably indicate that this aspect of the
deranged metabolism is acquired.
In conclusion, the present study demonstrates that glu-
cose effectiveness, as assessed during a prandial simulated
plasma glucose profile in the presence of near-basal circu-
lating insulin concentrations, is normal in FDR. This conclu-
sion is evident regardless of whether glucose effectiveness is
assessed as the glycemic increment above basal during glu-
cose infusion or whether cold and hot indexes of minimal
model parameters are determined. This study also demon-
strates that fasting endogenous glucose release and gluco-
neogenesis are unaltered in slightly hyperinsulinemic FDR and
that hyperglycemia per se restrains endogenous glucose
release equally in both groups. Taken together, our results sug-
gest that insulin resistance is the key defect in hepatic and
muscle glucose metabolism in glucose-tolerant FDR.
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